Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Open original source
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Open original source